A Single Autologous Stem Cell Transplant (ASCT) Followed by Two Years of Post-Transplant Therapy in Older Recently Diagnosed Multiple Myeloma (MM) Patients. Safety and Response Results From the Prospective Phase II Trial (NCT01849783)
Biology of Blood and Marrow Transplantation - Netherlands
doi 10.1016/j.bbmt.2018.12.793
Full Text
Open PDFAbstract
Available in full text
Date
March 1, 2019
Authors
Publisher
Elsevier BV